查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
RNAi技術市場按應用（藥物發現和開發,治療）,地區（北美,歐洲,亞太,中東和非洲,南美）,規模,份額,展望,機會分析2022-2028
市場調查報告書
商品編碼
1149833

RNAi技術市場按應用（藥物發現和開發,治療）,地區（北美,歐洲,亞太,中東和非洲,南美）,規模,份額,展望,機會分析2022-2028

RNAi Technology Market, By Application (Drug Discovery and Development and Therapeutics), By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

近年來，利用RNA的治療方法備受關注，有望治療心血管疾病、癌症、糖尿病、肺結核、艾滋病等多種疾病，以及罕見病和遺傳病。RNAi 也有望治療病毒性疾病，如人類免疫缺陷病毒 (HIV) 和丙型肝炎病毒 (HCV)。此外，RNAi 目前用於生物學和生物醫學研究，以檢查阻斷特定基因表達的影響。

市場動態。

慢性病患病率上升、對 RNAi 療法開發的關注度增加、分子診斷中應用數量的增加、RNAi 療法的頻繁批准、預計在預測期內爆發的 COVID-19 是預計將推動全球增長的主要因素RNAi 技術市場。

例如，2022 年 6 月，Alnylam Pharmaceuticals, Inc 宣布每三個月皮下注射一次，用於治療成人遺傳性轉甲狀腺素蛋白介導的 (hATTR) 澱粉樣變性多發性神經病。美國食品和藥物管理局 (FDA) 已宣布將要給藥的 RNAi 治療藥物“AMVUTTRA”已獲得批准。此外，2018 年 8 月，美國食品和藥物管理局 (FDA) 批准了 Alnylam Pharmaceuticals 的 Onpattro，這是一種 RNAi 療法，用於治療患有一種罕見的致命遺傳病，稱為遺傳性轉甲狀腺素蛋白介導的澱粉樣變性病。我來了。

這項研究的主要特點

  • 本報告對全球 RNAi 技術市場進行了深入分析，提供了以 2021 年為基準年的預測期 (2022-2028) 的市場規模和復合年增長率 (CAGR%)。
  • 它還揭示了不同細分市場的潛在創收機會，並描述了該市場具有吸引力的投資建議矩陣。
  • 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
  • 根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數，了解全球 RNAi 技術市場主要參與者的概況。
  • 本研究涵蓋的主要公司包括 Dicerna Pharmaceuticals Inc.、Phio Pharmaceuticals Corp.、Arcturus Therapeutics、Ionis Pharmaceuticals Inc.、Sigma Aldrich (Merck KGaA)、Benitec Biopharma Ltd.、Silence Therapeutics PLC、QIAGEN、SBI Biotech Co. Ltd.、Alnylam Pharmaceuticals Inc. 和 Thermo Fisher Scientific Inc. 等。
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。.
  • 全球 RNAi 技術市場報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球 RNAi 技術市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 市場概況：按應用分類
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

  • 市場動態
    • 增加對 RNAi 療法的認可
    • 嚴格的規章制度
    • COVID-19 爆發（大流行）
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章 RNAi 技術的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學特徵
  • 供應方和需求方分析
  • 經濟影響

第 5 章 RNAi 技術的全球市場，按應用分類，2017-2028

  • 藥物發現和開發
  • 治療藥物

第 6 章。2017-2028 年按地區分列的 RNAi 技術全球市場

  • 北美
  • 歐洲
  • 亞太地區
  • 世界其他地方

第七章競爭格局

  • QIAGEN
  • Dicerna Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Arcturus Therapeutics
  • Ionis Pharmaceuticals Inc.
  • Sigma Aldrich（Merck KGaA）
  • Benitec Biopharma Ltd.
  • Silence Therapeutics PLC
  • SBI Biotech Co. Ltd.
  • Alnylam Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.

第 8 章

  • 調查方法介紹
  • 關於出版商
簡介目錄
Product Code: CMI5281

RNA based therapeutics have garnered significant attention in recent years due to its potential to treat a variety of disease such as cardiovascular disease, cancer, diabetes, TB, AIDS, as well as rare and genetic disorders. RNAi also has the potential to treat viral diseases such as those caused by the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Moreover, RNAi is now being used in biological and biomedical research to study the effect of blocking expression of a given gene.

Market Dynamics:

Increasing prevalence of chronic diseases, rise in focus on RNAi therapeutic development, rise in number of applications in molecular diagnostics, frequent approvals of RNAi therapeutics, and the outbreak of COVID-19 are major factors expected to drive growth of the global RNAi technology market over the forecast period.

For instance, in June 2022, Alnylam Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA, an RNAi therapeutic administered via subcutaneous injection once every three months for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Moreover, in August 2018, The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals' Onpattro, an RNAi therapeutic for individuals with a rare and deadly genetic disorder called hereditary transthyretin-mediated amyloidosis.

Key features of the study:

  • This report provides in-depth analysis of the global RNAi technology market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global RNAi technology market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Dicerna Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Arcturus Therapeutics, Ionis Pharmaceuticals Inc., Sigma Aldrich (Merck KGaA), Benitec Biopharma Ltd., Silence Therapeutics PLC, QIAGEN, SBI Biotech Co. Ltd., Alnylam Pharmaceuticals Inc., and Thermo Fisher Scientific Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market.

Detailed Segmentation:

  • Global RNAi Technology Market, By Application:
    • Drug Discovery and Development
    • Therapeutics
  • Global RNAi Technology Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • QIAGEN
    • Dicerna Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Arcturus Therapeutics
    • Ionis Pharmaceuticals Inc.
    • Sigma Aldrich (Merck KGaA)
    • Benitec Biopharma Ltd.
    • Silence Therapeutics PLC
    • SBI Biotech Co. Ltd.
    • Alnylam Pharmaceuticals Inc.
    • Thermo Fisher Scientific Inc.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Application
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing approvals for RNAi therapeutics
    • Stringent rules and regulations
    • The outbreak of COVID-19 (pandemic)
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global RNAi Technology Market - Impact of Coronavirus (Covid-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global RNAi Technology Market, By Application, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Drug Discovery and Development
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global RNAi Technology Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

7. Competitive Landscape

  • QIAGEN
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dicerna Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Phio Pharmaceuticals Corp.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Arcturus Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ionis Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sigma Aldrich (Merck KGaA)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Benitec Biopharma Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Silence Therapeutics PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • SBI Biotech Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Alnylam Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

8. Section

  • Research Methodology
  • About us